Embedded Files
DelveInsight's comprehensive "CAR T-Cell Therapy Pipeline Analysis 2025" delivers extensive intelligence on over 180 organizations and more than 200 developmental drugs within the CAR T-Cell Therapy sector. The analysis encompasses detailed profiles of CAR T-Cell Therapy pipeline candidates across both clinical and preclinical phases. Coverage includes therapeutic evaluation by product classification, developmental phase, administration method, and molecular category. The report also spotlights dormant pipeline assets in this therapeutic area.
Interested in the most recent developments in CAR T-Cell Therapy Pipeline? Discover the treatments and studies generating attention @ CAR T-Cell Therapy Pipeline Outlook Report
Major Highlights from the CAR T-Cell Therapy Pipeline Analysis
Major Highlights from the CAR T-Cell Therapy Pipeline Analysis
On November 5, 2025, Cartesian Therapeutics revealed that the AURORA Study is assessing the safety profile, tolerability, and effectiveness of an experimental mRNA CAR T-cell treatment designated as Descartes-08 in adult patients with acetylcholine receptor autoantibody-positive generalized myasthenia gravis. The initial segment of the study will span approximately 6 months. Qualifying participants will continue into Part 2, which will extend for roughly 8 months.
On October 29, 2025, Juno Therapeutics Inc. launched a trial to assess the effectiveness, safety profile, and pharmacokinetics of CC-97540 in individuals with active systemic lupus erythematosus (SLE), including lupus nephritis, who have shown inadequate response to glucocorticoids and a minimum of 2 immunosuppressive agents.
On October 29, 2025, Kyverna Therapeutics commenced a clinical investigation of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for individuals with Refractory Lupus Nephritis. Systemic lupus erythematosus (SLE) represents a chronic autoimmune condition distinguished by diverse organ involvement and variable disease severity. Kidney involvement (classified as lupus nephritis [LN]) affects roughly 50% of SLE individuals and presents with proteinuria, microscopic hematuria, and varying levels of renal impairment.
On October 28, 2025, Novartis Pharmaceuticals initiated a trial to track all individuals who received CAR-T therapies for 15 years after their final CAR-T (such as CTL019) administration to evaluate the potential for delayed adverse events (AEs), screen for replication competent lentivirus (RCL), and measure long-term effectiveness, including vector persistence.
DelveInsight's CAR T-Cell Therapy Pipeline analysis illustrates a dynamic landscape with over 180 active organizations working to advance more than 200 pipeline treatments for CAR T-Cell Therapy applications.
The prominent CAR T-Cell Therapy Organizations include Cartesian Therapeutics, Arcellx, Inc, Nexcella, Inc, Autolus Therapeutics, Sana Biotechnology, Orgenesis, CARsgen, TILT Biotherapeutics, Poseida Therapeutics, Precision BioSciences, Novartis, Kyverna Therapeutics, Cemacabtagene ansegedleucel, Hrain Biotechnology, UTC Therapeutics, Kiromic, Suzhou Fundamenta Therapeutics, Gracell Biotechnology, CARsgen, Innovent Biologics/Nanjing IASO Biotherapeutics, CellabMED, Umoja Biopharma, TC BioPharm, ElevateBio, Century Therapeutics and additional entities.
Notable CAR T-Cell Therapy Treatments include Itacitinib, Cyclophosphamide, Fludarabine, WU-CART-007, Cevostamab, JNJ-68284528, Lenalidomide, Daratumumab, KYV-101, Epcoritamab, and additional candidates.
Curious about which organizations are pioneering innovation in CAR T-Cell Therapy? Explore the complete pipeline intelligence @ CAR T-Cell Therapy Clinical Trials Assessment
CAR T-Cell Therapy Background
CAR T-Cell Therapy Background
CAR T-cells represent fusion proteins combining a selected single-chain fragment variable from a specific monoclonal antibody with one or more T-cell receptor intracellular signaling domains. A CAR integrates antigen-binding domains—typically, a single-chain variable fragment (scFv) obtained from the variable domains of antibodies—with the signaling domains of the TCR chain and supplementary costimulatory domains from receptors, including CD28, OX40, and CD137. CAR T cells possess the potential to eliminate all malignant cells throughout the body and may persist within the body for months following infusion.
CAR T-Cell Therapy Emerging Drug Profiles
CAR T-Cell Therapy Emerging Drug Profiles
Descartes-08: Cartesian Therapeutics
Descartes-08 represents an mRNA-modified, autologous CAR T-cell product targeting B-Cell Maturation Antigen (BCMA) that employs a novel modality and mechanism of action for addressing gMG and other autoimmune conditions. Descartes-08 distinguishes itself from anti-B-cell agents, which fail to address long-lived plasma cells, and from FcRn blockers or complement inhibitors, which intervene only after autoantibody production and pathogenic mediator amplification. Descartes-08 aims to stop autoantibody production by targeting pathogenic long-lived plasma cells capable of surviving for decades within the organism. Presently, the treatment is advancing through Phase II development for Myasthenia gravis (gMG).
CART-ddBCMA: Arcellx, Inc
CART-ddBCMA constitutes a genetically modified cellular therapy employing a novel synthetic binding domain that is computationally designed, highly stable, and engineered for reduced immunogenicity. CART-ddBCMA represents a Phase I investigation of Arcellx's BCMA-specific CAR-modified T-cell therapy utilizing the organization's novel BCMA-targeting binding domain for treating individuals with relapsed and refractory multiple myeloma. The Arcellx ddBCMA cellular therapy has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration. The Phase I investigation is actively recruiting patients. CART-ddBCMA demonstrated good tolerability and rapid, profound, and sustained responses at the initial dose level of 100 million cells, with six of six evaluable individuals responding according to IMWG criteria. Presently, the treatment is advancing through Phase II development for multiple myeloma.
NXC-201: Nexcella, Inc
NXC-201 (previously HBI0101) represents a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cellular therapy being examined in a comprehensive clinical development program for treating individuals with relapsed or refractory multiple myeloma and AL amyloidosis. NXC-201 (previously HBI0101) stands as the sole "Single-Day CRS" CAR-T cellular therapy uniquely positioned to target AL Amyloidosis and other autoimmune conditions. It is being examined in a comprehensive clinical development program for treating individuals with relapsed/refractory AL amyloidosis, and extending into other autoimmune indications. These trials build upon a substantial NXC-201 clinical dataset initiated in February 2021. NXC-201 has received Orphan Drug Designation (ODD) from the FDA in both AL Amyloidosis and multiple myeloma, and received EU ODD from the EMA in AL Amyloidosis. Presently, the treatment is advancing through Phase I/II development for AL Amyloidosis and multiple myeloma.
AUTO-8: Autolus Therapeutics
AUTO8 represents the next-generation product candidate for multiple myeloma comprising two independent CARs for the multiple myeloma targets, BCMA and CD19. The organization has developed an optimized BCMA CAR designed for enhanced killing of target cells expressing BCMA at low concentrations. This has been combined with fast off-rate CD19 CAR from one-cell. The organization believes that the design of AUTO8 possesses the potential to induce profound and sustained responses and extend the durability of effect beyond other BCMA CARs currently under development. Presently, the treatment is advancing through Phase I development for multiple myeloma.
SG299: Sana Biotechnology
SG299 represents the initial drug candidate from the fusogen platform in generating CD19-directed CAR T cells with in vivo delivery. In 2023, anticipate preliminary clinical data for SC291, allogeneic CAR T cells for individuals with B cell cancers; submission of an IND for SC262, allogeneic CAR T cells for individuals who have failed previous CAR T therapy; and submission of an IND for SG299, in vivo CAR delivery program for individuals with B cell cancers. Presently, the treatment is advancing through Preclinical development for chronic lymphocytic leukemia.
If you're monitoring ongoing CAR T-Cell Therapy Clinical trials, this press release is essential reading. Access to see the breakthroughs @ CAR T-Cell Therapy Treatment Drugs
The CAR T-Cell Therapy Pipeline Analysis Provides Intelligence Into:
The CAR T-Cell Therapy Pipeline Analysis Provides Intelligence Into:
The analysis delivers detailed intelligence about organizations developing therapies for CAR T-Cell Therapy treatment with aggregate therapies developed by each organization for the same.
It evaluates the various therapeutic candidates segmented into early-phase, mid-phase, and late-phase of development for CAR T-Cell Therapy Treatment.
CAR T-Cell Therapy Organizations are engaged in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
CAR T-Cell Therapy Drugs under development categorized by the developmental phase, administration method, target receptor, monotherapy or combination therapy, various mechanisms of action, and molecular classification.
Comprehensive analysis of partnerships (organization-organization partnerships and organization-academia partnerships), licensing agreements, and financing details for future progression of the CAR T-Cell Therapy market.
CAR T-Cell Therapy Organizations
CAR T-Cell Therapy Organizations
Cartesian Therapeutics, Arcellx, Inc, Nexcella, Inc, Autolus Therapeutics, Sana Biotechnology, Orgenesis, CARsgen, TILT Biotherapeutics, Poseida Therapeutics, Precision BioSciences, Novartis, Kyverna Therapeutics, Cemacabtagene ansegedleucel, Hrain Biotechnology, UTC Therapeutics, Kiromic, Suzhou Fundamenta Therapeutics, Gracell Biotechnology, CARsgen, Innovent Biologics/Nanjing IASO Biotherapeutics, CellabMED, Umoja Biopharma, TC BioPharm, ElevateBio, Century Therapeutics and additional entities.
CAR T-Cell Therapy Pipeline Analysis Delivers Therapeutic Evaluation by Route of Administration
CAR T-Cell Therapy Pipeline Analysis Delivers Therapeutic Evaluation by Route of Administration
Products have been classified under various ROAs including:
Oral
Intravenous
Subcutaneous
Parenteral
Topical
CAR T-Cell Therapy Products Have Been Classified Under Various Molecular Types Including:
CAR T-Cell Therapy Products Have Been Classified Under Various Molecular Types Including:
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
From emerging drug candidates to competitive intelligence, the CAR T-Cell Therapy Pipeline Analysis covers everything – review it now @ CAR T-Cell Therapy Market Drivers and Barriers, and Future Perspectives
Scope of the CAR T-Cell Therapy Pipeline Analysis
Scope of the CAR T-Cell Therapy Pipeline Analysis
Coverage: Global
CAR T-Cell Therapy Organizations: Cartesian Therapeutics, Arcellx, Inc, Nexcella, Inc, Autolus Therapeutics, Sana Biotechnology, Orgenesis, CARsgen, TILT Biotherapeutics, Poseida Therapeutics, Precision BioSciences, Novartis, Kyverna Therapeutics, Cemacabtagene ansegedleucel, Hrain Biotechnology, UTC Therapeutics, Kiromic, Suzhou Fundamenta Therapeutics, Gracell Biotechnology, CARsgen, Innovent Biologics/Nanjing IASO Biotherapeutics, CellabMED, Umoja Biopharma, TC BioPharm, ElevateBio, Century Therapeutics and additional entities.
CAR T-Cell Therapy Treatments: Itacitinib, Cyclophosphamide, Fludarabine, WU-CART-007, Cevostamab, JNJ-68284528, Lenalidomide, Daratumumab, KYV-101, Epcoritamab, and additional candidates.
CAR T-Cell Therapy Therapeutic Evaluation by Product Type: Mono, Combination, Mono/Combination
CAR T-Cell Therapy Therapeutic Evaluation by Clinical Phases: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research – discover what's next for the CAR T-Cell Therapy Treatment landscape in this detailed analysis @ CAR T-Cell Therapy Emerging Drugs and Major Players
Table of Contents
Table of Contents
Introduction
Executive Summary
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) : Overview
Pipeline Therapeutics
Therapeutic Assessment
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug name: Company Name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Descartes-08: Cartesian Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
NXC-201: Nexcella, Inc
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
SG299: Sana Biotechnology
Drug profiles in the detailed report…..
Inactive Products
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Key Companies
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Key Products
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Unmet Needs
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Market Drivers and Barriers
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Future Perspectives and Conclusion
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Analyst Views
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Key Companies
Appendix
About Us
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Contact Us
Kanishk
kkumar@delveinsight.com
Page updated
Google Sites
Report abuse